Enhancing efficacy of HIV Gag DNA vaccine by local delivery of GM-CSF in murine and macaque models

Journal of Interferon and Cytokine Research

Volumn 26, Issue 6, 2006, Pages 380-389

  Song, Ruijiang ^a   Liu, Shuqin ^a   Adams, Robert J ^a   Leong, Kam W ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 726 Ross Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DNA VACCINE; FREUND ADJUVANT; GAG P55 PROTEIN; GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED DRUG RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL PRIMING; IMMUNOSTIMULATION; MACACA; MICROPARTICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ALBUMINS; ANIMALS; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENE PRODUCTS, GAG; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HEPARIN; HIV; HUMANS; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MICE; MICE, INBRED BALB C; MICROSPHERES; MODELS, ANIMAL; MUSCLE, SKELETAL; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, DNA;

ANIMALIA; MACACA MULATTA; MURINAE;

EID: 33744960517     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.380     Document Type: Article

References (38)

1. Sewell AK, Price DA, Oxenius A, Kelleher AD, Phillips RE. Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape. Stem Cells 2000;18:230-244.
2. Wick WD, Yang OO, Corey L, Self SG. How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill? J. Virol. 2005;79:13579-13586.
3. (+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Exp. Med. 2000;191:1921-1931.
4. + lymphocytes. Science 1999;283:857-860.
5. Barouch DH, Powers J, Truitt DM, Kishko MG, Arthur JC, Peyerl FW, Kuroda MJ, Gorgone DA, Lifton MA, Lord CI, Hirsch VM, Montefiori DC, Carville A, Mansfield KG, Kunstman KJ, Wolinsky SM, Letvin NL. Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants. Nat. Immunol. 2005;6:247-252.
6. Boyer JD, Chattergoon M, Muthumani K, Kudchodkar S, Kim J, Bagarazzi M, Pavlakis G, Sekaly R, Weiner DB. Next generation DNA vaccines for HIV-1. J. Liposome Res. 2002;12:137-142.
7. Nabel GJ. HIV vaccine strategies. Vaccine 2002;20:1945-1947.
8. Lian Y, Srivastava I, Gomez-Roman VR, Zur Megede J, Sun Y, Kan E, Hilt S, Engelbrecht S, Himathongkham S, Luciw PA, Otten G, Ulmer JB, Donnelly JJ, Rabussay D, Montefiori D, van Rensburg EJ, Barnett SW. Evaluation of envelope vaccines derived from the Soulh African subtype C human immunodeficiency virus type 1 TV1 strain. J. Virol. 2005;79:13338-13349.
9. Lewis PJ, Babiuk LA. DNA vaccines: a review. Adv. Virus Res. 1999;54:129-188.
10. Donnelly JJ, Ulmer JB. DNA vaccines for viral diseases. Braz. J. Med. Biol. Res. 1999;32:215-222.
11. Fong CL, Mok CL, Hui KM. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression. Gene Ther. 2006;13:245-256.
12. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T cell immunogenicity and protective efficacy of a human immunodeficiency virus type I vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 1998;72:10180-10188.
13. Lu S, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, Haynes JR, Letvin NL, Wyand M, Robinson HL. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 1996;70:3978-3991.
14. Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J. Immunol. 1997;158:3947-3958.
15. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD, Weiner DB. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J. Immunol. 1997;158:816-826.
16. Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol. Immunother. 2005;55:672-683.
17. Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Thomas EK, Berzofsky JA. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc. Natl. Acad. Sci. USA 2002;99:13020-13025.
18. Weiss WR, Ishii KJ, Hedstrom RC, Sedegah M, Ichino M, Barnhart K, Klinman DM, Hoffman SL. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J. Immunol. 1998;161:2325-2332.
19. Metcalf D, Begley CG, Nicola NA. The proliferative effects of human GM-CSF alpha and beta and murine G-CSF in microwell cultures of fractionated human marrow cells. Leuk. Res. 1985;9:521-527.
20. Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J. Immunol. 1987;139:1113-1119.
21. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258-261.
22. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 1992;79:2849-2854.
23. Sedegah M, Charoenvit Y, Aguiar J, Sacci J, Hedstrom R, Kumar S, Belmonte A, Lanar DE, Jones TR, Abot E, Druilhe P, Corradin G, Epstein JE, Richie TL, Carucci DJ, Hoffman SL. Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun. 2004;5:553-561.
24. Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK, Pavlakis GN, Yu XF. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J. Virol. 1999;73:9145-9152.
25. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao YF, Miyazono K, Urabe A, Takaku F. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 1989;140:323-334.
26. Yasutomi Y, Robinson HL, Lu S, Mustafa F, Lekutis C, Arthos J, Mullins JI, Voss G, Manson K, Wyand M, Letvin NL. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J. Virol. 1996;70:678-681.
27. Liu SQ, Aoki H, Ohno T, Leong K. Generation of tumor-specific cytotoxic T lymphocytes from naive mouse splenocytes in vitro. 89th Annual Meeting of American Association for Cancer Research. 1998;612.
28. Pettit DK, Lawter JR, Huang WJ, Pankey SC, Nightlinger NS, Lynch DH, Schuh JA, Morrissey PJ, Gombotz WR. Characterization of poly(glycolide-co-D,L- lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF. Pharm. Res. 1997;14:1422-1430.
29. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
30. Karanikas V, Rowley MJ, MacKay IR, Loveland BE. Autoreactive cytotoxic T cells in mice are induced by immunization with a conserved mitochondrial enzyme in Freund's complete adjuvant. Immunology 1999;97:264-271.
31. Fernando GJ, Stewart TJ, Tindle RW, Frazer IH. Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term, whereas preexisting Th2 responses are dominant in the longer term. Scand. J. Immunol. 1998;47:459-465.
32. + cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants. Vaccine 1999;17:2974-2982.
33. Skinner MA, Prestidge R, Yuan S, Strabala TJ, Tan PL. The ability of heat-killed Mycobacterium vaccae to stimulate a cytotoxic T-cell response to an unrelated protein is associated with a 65 kilodalton heat-shock protein. Immunology 2001;102:225-233.
34. Men Y, Tamber H, Audran R, Gander B, Corradin G. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Vaccine 1997;15:1405-1412.
35. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AM. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 1994;81:661-667.
36. Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY, O'Hagan D. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996;14:1523-1530.
37. Kuang M, Liu SQ, Saijo K, Uchimura E, Huang L, Leong KW, Lu MD, Huang JF, Ohno T. Microwave tumour coagulation plus in situ treatment with cytokine microparticles: induction of potent anti-residual tumour immunity. Int. J. Hyperthermia 2005;21:247-257.
38. Peng BG, Liu SQ, Kuang M, He Q, Totsuka S, Huang L, Huang J, Lu MD, Liang LJ, Leong KW, Ohno T. Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn. J. Cancer Res. 2002;93:363-368.